During the 14th five-year plan (2021–2025), the average annual increase in spending by China's health insurance funds on new medicines, or innovative medicines purchased through public procurement following price negotiations with pharmaceutical companies, amounted to 40%. Zhang Ke, head of the State Administration of Medical Support of the People's Republic...
